Nervous Disorder TRIZ Cases

CyP40 uses prolyl isomerase activity to disaggregate tau and α-synuclein fibrils without ATP-dependent complexes, reducing neurotoxicity.

Specific SARM1 substitutions create dominant negative variants that inhibit endogenous SARM1 activity and preserve axon integrity in neurological disorders.

Targeted HC mutations shift BoNT/B binding toward human Syt II and away from Syt I, improving neuronal specificity while reducing diffusion-related effects.

Taking MCTs about 30 minutes before a meal raises blood ketones more effectively while reducing gastrointestinal discomfort.

Combining omega-3, vitamin D, and homocysteine markers improves cognitive decline risk identification and guides multi-pathway therapy.

Using EGF or TGF-α as the CAR binding domain helps EGFR CAR-T cells improve antitumor activity with minimal toxicity across EGFR variants.

A microwave absorbing agent heats plant material indirectly, enabling oil and oleoresin distillation without combustion or thermal degradation.

Altered C9ORF72-linked gene expression enables earlier ALS and FTD diagnosis and targeted modulation to slow neurodegeneration.

Sublytic CDC dosing modulates TBI neuroinflammation without hemolysis, improving neural plasticity, synaptic strength, and cognition.

Measuring TIMP-1, MCP-1, GROα, and IL-6 identifies stem cells with stronger regenerative and angiogenic effects for neurological disease treatment.

Ondansetron blocks pramipexole-related nausea and vomiting, enabling higher antidepressant doses with better patient tolerance.

Agonist anti-PD-1 antibodies enhance PD-1 and PD-L1 signaling to suppress T cells and lower inflammatory cytokines in autoimmune disorders.

Inflammation, oxidative stress, insulin resistance, and autophagy biomarkers support earlier Alzheimer's diagnosis and targeted treatment choice.

Microfluidic PEGylation helps rHDL nanoparticles avoid immune uptake, extend blood circulation, and preserve blood-brain barrier transport.

POH carbamate conjugates pair perillyl alcohol with chemotherapeutics to target resistant glioma cells and inhibit tumor growth.

A tick salivary gland polypeptide reduces neuroinflammation and secondary brain injury after ICH without increasing hemorrhage or edema.

A cannabidiol and buprenorphine combination relieves chronic pain and anxiety while lowering opioid dose needs and overdose risk.

Using gliclazide for psychotic symptoms offers an alternative to antipsychotics by reducing delusions and agitation with fewer side effects.

Sequencing radiation before mutant IDH inhibitor therapy helps avoid desensitization while improving glioma control and survival.

Selective D/L amino acid design and TAT-linked structure improve PSD-95 inhibitor stability, activity, and plasma half-life.

NR2B-selective guanidine compounds relieve chronic pain by blocking NMDA signaling while helping prevent opioid tolerance and addiction.

Selective C5aR blockade prevents chemotherapy-induced allodynia and sensory neuron damage while preserving the anticancer action of chemotherapeutic drugs.

Higher-volume extramuscular botulinum toxin dosing targets head and neck nerve zones to improve migraine coverage while limiting paralysis.

A substituted pyridazine composition improves NLRP3 inflammasome inhibition to support treatment of inflammatory and neurodegenerative diseases.

Nasal rifampicin and resveratrol suppress TDP-43 and DPR aggregation, reducing RNA foci and neuronal degeneration in ALS models.

Targeting TRPA1 with 3-aryloxy heteroaryl propylamine compounds offers pain relief for chronic and inflammatory pain with fewer side effects.

Genetically modified adipocytes over-expressing FFAR4 improve glucose tolerance and help preserve cognitive function in aging.

Combining cucurbituril-like sequestration agents with naloxone clears opioids faster and helps prevent renarcotization and withdrawal.

A priming IV dose and enzyme-free adipose SVF processing help reduce lung trapping, contamination risk, and improve stem cell distribution.

Conformationally constrained agonists improve 5-HT2C selectivity while minimizing 5-HT2A and 5-HT2B activation linked to CNS drug side effects.

IL-10 overexpression helps transplanted MSCs survive and engraft more reliably while reducing adverse reactions and supporting durable gene expression.

Selective hyposialylation and ion-exchange purification of rhEPO improve neuroprotection while avoiding hematopoietic adverse events.

Variegated A2A receptor antibody libraries address low GPCR expression and purification instability to enable high-affinity cancer and neurology binders.

A choline-succinate and nicotinamide composition helps succinate cross the blood-brain barrier to boost ATP, NADH, and mental concentration.

Optimized 2-aminoquinazoline compounds balance potent, selective LRRK2 inhibition with brain penetration for neurodegenerative disease treatment.

Metabolically labile thioether MDMA analogs shorten 4-6 hour action through rapid enzymatic oxidation while preserving therapeutic use.

AAV delivery of GBA, LIMP2, and prosaposin boosts lysosomal function and lowers α-synuclein buildup in Parkinson's and Gaucher-related CNS disease.

Low-dose subcutaneous ofatumumab uses loading and maintenance dosing to control MS lesions while limiting infusion reactions and infection risk.

Electrophilic nitroalkene derivatives inhibit NF-κB in microglia to reduce neuroinflammation and slow paralysis in ALS models.

By blocking Netrin-1 binding to UNC5C, these antibodies reduce neuronal apoptosis and support synaptic and dopaminergic function.

Using BB-115 alone or with MP108 and BLI-02, this case boosts enterochromaffin 5-HTP secretion without supplement side effects.

Targeted C1/C2 ethylamine substitution and fused heterocycles help retain mescaline benefits while reducing panic, paranoia, and nausea.

Crystalline Risdiplam forms improve stability, dissolution, and handling through controlled polymorph preparation and characterization.

An Fc-linked p75NTR binding protein boosts neurotrophin binding, extends serum half-life, and reduces pain with lower dosing frequency.

Engineered rAAV capsids use TfR1-binding moieties to cross the blood-brain barrier and improve widespread CNS transduction after systemic delivery.

A two-dose nasal salt formulation balances self-administration simplicity with fast arrhythmia termination and limited side effects.

Ghrelin-treated mesenchymal stem cells raise AgRP expression to boost proteasome activity and help clear toxic proteins in brain disease.

Oral pridopidine at 90 mg/day helps preserve functional capacity, cognition, and quality of life in early-stage Huntington disease.

EEG-guided use of 5-HT2A, AMPA, and NMDA modulators helps match depression treatment to cognitive impairment and biomarker profiles.

SYNC2 fragments allosterically inhibit MFSD2A lipid uptake to raise BBB transcytosis and enable brain delivery of therapeutic cargo.